Argus Research analyst Jasper Hellweg maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday. The company’s shares ...

Evercore ISI analyst Umer Raffat maintained a Hold rating on Eli Lilly & Co (LLY – Research Report) yesterday. The company’s shares closed ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

We recently published a list of 12 Stocks That Could Split in the Near Future. In this article, we are going to take a look ...

PROVIDENCE, R.I. (AP) Kino Lilly Jr. had 16 points in Brown's 98-57 victory against Johnson & Wales on Sunday. Lilly also added eight assists for the Bears (8-5). N'famara Dabo scored 12 points ...

"After five years of working at Republic Garden and Lounge, Grace Lilly has exited the building," she shared in a confessional. "I've been doing some modeling and I just want to do like ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

Senior equity analysts at StockNews.com upgraded Eli Lilly (LLY, Financial) stock from 'hold' to 'buy' as its stock has shifted positively. Analysts say the upgrade is a sign of increased ...

Lilly seeks to protect interests in compounded drug case FDA affirms no shortage of tirzepatide drugs Compounded versions cheaper, often not covered by insurers Jan 2 (Reuters) - Eli Lilly (LLY.N ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

Now, to be clear, I am not clairvoyant, and I missed on plenty of my busts picks in 2024: Here, you can look for yourself to see that I went on the internet and called Elly De La Cruz (No. 7 ...

Zepbound, as expected, was more effective in promoting weight loss. Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...